This Week in Infectious Disease — Jun 25, 2026

Welcome to This Week in Infectious Disease. This week we're covering 10 notable papers spanning global outbreak modeling and vector dynamics, novel therapeutic strategies for chronic viral and bacterial infections, and emerging diagnostic and environmental health insights. Let's dive in.

We begin with critical updates on infectious disease epidemiology and vector transmission across the African continent. In a modeling study published in The Lancet Infectious Diseases, researchers analyzed the 2026 Bundibugyo virus outbreak in Ituri Province, Democratic Republic of the Congo [1]. Using a calibrated stochastic model anchored on nearly six hundred confirmed cases in early June, the investigators projected a median of nine hundred and ninety cumulative confirmed cases and one hundred and seventy-four deaths by late June under their central scenario. Crucially, the model demonstrated a highly elevated risk of cross-border spillover, with a ninety-four percent probability of importation into Uganda, where cases have already been established, and a sixty-nine percent probability for South Sudan. This underscores the urgent need for neighboring countries to reinforce rapid response capacities and cross-border surveillance under International Health Regulations. Meanwhile, the journal Science features a genomic analysis that traces the origin and rapid expansion of the invasive urban malaria vector, Anopheles stephensi, which threatens over one hundred and twenty million city-dwellers in Africa [2]. By analyzing more than six hundred whole genomes, researchers mapped an invasion pathway starting from an initial South Asian introduction into Djibouti, which subsequently seeded distinct invasion fronts in Sudan, Yemen, and the Ethiopia-Kenya region. Alarmingly, the study revealed that insecticide resistance in these populations is predominantly driven by metabolic detoxification genes, with resistance haplotypes and copy-number amplifications directly imported from South Asia. This highlights the critical necessity of genomic surveillance to guide vector control strategies. Turning to sexually transmitted infections, a massive systematic review and meta-analysis in PLoS Medicine synthesized over six decades of data on Neisseria gonorrhoeae prevalence in sub-Saharan Africa [4]. The study revealed a pooled urogenital prevalence of just over three percent in the general population, but highlighted exceptionally high burdens in key populations, including an eleven percent urogenital prevalence among female sex workers and an eight percent anorectal prevalence among men who have sex with men. Symptomatic men showed a striking fifty-one percent urogenital prevalence. While the meta-regression indicated a long-term decline in prevalence of approximately one percent per year, the persistently high burden emphasizes the need for expanded diagnostic access and continued vigilance against antimicrobial resistance.

Next, we look at significant advances in therapeutic development and the underlying mechanics of pathogen survival. In a major clinical breakthrough, The New England Journal of Medicine published the phase three results of two replicate trials, B-Well 1 and B-Well 2, evaluating bepirovirsen for chronic hepatitis B virus infection [8]. Bepirovirsen, an antisense oligonucleotide targeting viral transcripts, was administered weekly for twenty-four weeks to adults on stable nucleoside or nucleotide analogue therapy. At seventy-two weeks, which was twenty-four weeks after discontinuing analogue therapy, a functional cure—defined as sustained hepatitis B surface antigen loss and undetectable viral DNA—was achieved in twenty percent of patients in the first trial and nineteen percent in the second trial, compared to zero percent in the placebo groups. While these results are promising, clinicians should note that grade three or higher adverse events occurred in sixteen percent of the bepirovirsen group, with transient alanine aminotransferase elevations being the most common. In the realm of drug discovery, a study in Nature describes how Streptomyces species utilize a highly conserved biosynthetic megacluster to deploy a naturally evolved combination therapy [3]. Instead of producing a single bioactive molecule, this megacluster coordinates the production of four distinct chemical families alongside the biotin-binding protein streptavidin. These elements work in synergy to target bacterial biotin metabolism through multiple mechanisms, demonstrating enhanced efficacy against multidrug-resistant Escherichia coli in mouse models and opening a new paradigm for reconstructing native synergistic systems. This concept of pathogen-driven metabolic manipulation is mirrored in host-pathogen interactions. Writing in Cell, researchers demonstrated how enterotoxigenic Bacteroides fragilis, a classically anaerobic bacterium linked to colitis and colorectal cancer, actively rewires host metabolism to survive in the inflamed gut [10]. The pathogen uses its signature toxin to shift the colonic epithelium from oxidative phosphorylation to glycolysis, creating a localized oxidative niche rich in lactate and oxygen that fuels the pathogen's own growth. Understanding these metabolic and pathogenic traits is increasingly relevant as we recognize the broader systemic impacts of common pathogens. A review in Nature Reviews Microbiology details how the Klebsiella genus acts as a major driver of human disease, not only causing acute healthcare-associated infections like pneumonia and bacteremia, but also contributing to non-communicable disorders including chronic inflammatory diseases, metabolic disorders, and cancer [5]. The authors emphasize the need for diverse targeting strategies, from bacteriophages and live biotherapeutics to strict infection control practices.

Finally, we examine how advanced imaging and epidemiological tracking are reshaping clinical staging and public health priorities. A study in Clinical Infectious Diseases evaluated the role of fluorodeoxyglucose positron emission tomography-computed tomography, or FDG-PET/CT, in staging paracoccidioidomycosis, a neglected systemic mycosis [6]. In a cohort of thirty-four patients, PET/CT detected more than twice as many lesions as conventional staging methods and led to a dramatic clinical reclassification, identifying ninety-seven percent of patients as having multifocal disease compared to just fifty-nine percent by standard evaluation. This resulted in a significant upward shift in disease severity classification, with the proportion of patients classified as severe rising from seventy percent to ninety-one percent, directly impacting the recommended duration of antifungal therapy. In the public health sector, The Lancet Global Health published updated World Health Organization estimates on the global burden of nine foodborne chemical hazards from 2000 to 2021 [7]. In 2021 alone, these dietary chemical exposures caused over six million cases of illness and more than one million deaths globally, with inorganic arsenic and lead accounting for the vast majority of deaths, primarily through cardiovascular disease. This highlights the critical need to integrate food safety with broader non-communicable disease prevention efforts. Lastly, we note a Danish nationwide cohort study published in The Lancet Infectious Diseases evaluating the effectiveness of the BNT162b2 LP.8.1-adapted SARS-CoV-2 vaccine against COVID-19-associated hospitalization and death [9]. While the published abstract does not detail specific efficacy rates, this study represents ongoing efforts to monitor and validate updated vaccine formulations in real-world populations.

If you only have time for one paper this week, make it the phase three trials of bepirovirsen for chronic hepatitis B in The New England Journal of Medicine [8]. This study provides robust clinical evidence that a finite, twenty-four-week course of an antisense oligonucleotide can achieve a functional cure in roughly one in five patients, representing a monumental shift in how we might soon manage chronic hepatitis B in clinical practice.

Here are the key takeaways from this week in Infectious Disease.

First, the phase three trials of bepirovirsen demonstrate that targeting viral transcripts with antisense oligonucleotides can achieve a functional cure in approximately twenty percent of patients with chronic hepatitis B, though close monitoring for liver enzyme flares is required.

Second, when staging patients with paracoccidioidomycosis, utilizing FDG-PET/CT reveals more than double the number of lesions compared to conventional staging, frequently reclassifying patients to a higher severity level and altering treatment duration.

Third, the invasive urban malaria vector, Anopheles stephensi, is rapidly spreading across Africa from an initial South Asian introduction, carrying metabolic insecticide resistance genes that threaten current vector control programs.

Finally, the 2026 Bundibugyo Ebola outbreak in the Democratic Republic of the Congo carries a high risk of cross-border transmission, with models predicting over a ninety percent probability of spillover into Uganda and nearly seventy percent into South Sudan, necessitating immediate regional preparedness.

That's your roundup for This Week in Infectious Disease. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.